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Cancer Chemotherapy Trials
Paul Wheatley-Price, MBChB, MRCP,* Aure´lie Le Maître, MSc,† Keyue Ding, PhD,†
Natasha Leighl, MD,* Vera Hirsh, MD,‡ Lesley Seymour, MD,† Andrea Bezjak, MD,*
and Frances A. Shepherd, MD*, for the NCIC Clinical Trials Group
Background: Female sex is a favorable prognostic factor in lung
cancer. In small-cell lung cancer, women have been shown to
experience greater toxicity from chemotherapy, but there are few
studies of sex-related toxicity in non-small cell lung cancer
(NSCLC).
Patients and Methods: This retrospective analysis evaluated the
effect of sex on efficacy, adverse events (AEs), dose intensity (DI),
and quality of life (QoL) in three phase III NSCLC trials conducted
by the National Cancer Institute of Canada Clinical Trials Group;
BR.10 (adjuvant chemotherapy), BR.14, and BR.18 (first-line ad-
vanced disease). Only patients with National Cancer Institute of
Canada Clinical Trials Group data were included, and patients in the
BR.10 observation arm were excluded.
Results: Of 1108 patients analyzed, 29% were female. On study
entry, women were less likely to be overweight or obese (40%
versus 51%, p 0.0001), more likely to have adenocarcinoma (70%
versus 44%, p  0.0001), and less likely to be anemic at baseline
(29% versus 55%, p  0.0001) or have medical comorbidities.
There were no significant differences in response rate to chemother-
apy (27% versus 31%, p  0.44 [excluding BR.10]), grade 3 or 4
AEs, DI, or QoL between sexes, although women reported more
nausea and vomiting of any grade (77% versus 66%, p  0.0004).
In multivariate analysis, women had longer progression-free sur-
vival than men (hazard ratio 0.83, 95% confidence interval 0.71–
0.97, p  0.02) but not overall survival (hazard ratio 0.89, 95%
confidence interval 0.75–1.05, p  0.17).
Conclusion: Women demonstrate modestly longer progression-free
survival than men in chemotherapy-treated NSCLC, with no differ-
ences observed in response rates, serious AEs, or QoL.
Key Words: Chemotherapy, Sex, Non-small cell lung cancer.
(J Thorac Oncol. 2010;5: 640–648)
Lung cancer is the most common cause of cancer deathworldwide, with more than one million cases annually.1,2 In
North America in 2008, there were more than 239,000 new
lung cancer cases, resulting in more than 181,000 deaths.3,4
Sex may influence outcomes of treatment for lung
cancer. In various tumor types, females have been shown to
experience greater toxicity from chemotherapy.5–10 Singh et
al. reported significant differences in toxicity to chemother-
apy in patients with small-cell lung cancer (SCLC) in an
analysis of National Cancer Institute of Canada Clinical
Trials Group (NCIC CTG) trials, where women experienced
significantly more hematologic and nonhematologic toxicity.
As in other SCLC studies, women also had significantly
improved response and overall survival (OS) from treatment.9
Improved survival in women has been reported in a number
of malignancies, including oral, colon, and esophageal cancer
and melanoma.11–14 Indeed, a recent analysis in the USA
reported that the 10-year risk of death from all causes com-
bined (heart disease, stroke, cancer, pneumonia, AIDS, acci-
dents, and chronic obstructive pulmonary disease) is higher
for men than women.15
The effect of sex on treatment outcomes in non-small
cell lung cancer (NSCLC) is less clear, with some but not
all studies reporting a more favorable outcome for women
compared with men.16–22 In this retrospective pooled anal-
ysis of NSCLC chemotherapy trials performed by the
NCIC CTG, we investigated the influence of sex on effi-
cacy, adverse events (AEs), dose delivery, and quality of
life (QoL).
PATIENTS AND METHODS
Studies Included and Treatment
Studies were selected for inclusion if they were ran-
domized phase III studies conducted by the NCIC CTG using
modern chemotherapy doublets. All trials received ethics
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board approval and all patients gave informed consent. All
patients, except those in the observation arm of BR.10, were
included for efficacy analysis if NCIC CTG held their data.
Patients who were randomized to receive chemotherapy but
received no cycles were excluded from the AE and QoL
analyses. The studies and their treatment arms are listed in
Table 1.
The BR.10 study investigated adjuvant cisplatin/vi-
norelbine chemotherapy versus observation in patients with
resected stage IB or stage II NSCLC.23 The BR.14 study was
a three-arm study, comparing cisplatin/vinorelbine or cispla-
tin/gemcitabine versus vinorelbine/gemcitabine in patients
with advanced (stage IIIB or IV) NSCLC. This trial was
conducted by the GEMVIN investigators (Naples, Italy, and
the NCIC CTG). Only the Canadian patients were included in
this analysis.24 The BR.18 study randomized patients with
advanced NSCLC (stage IIIB or IV) to carboplatin/paclitaxel
with either BMS-275291 (a broad-spectrum matrix metallo-
proteinase inhibitor) or placebo.25 Patients included in the
pooled analysis are shown in Figure 1.
FIGURE 1. Study flow diagram.
TABLE 1. NCIC Clinical Trials Group NSCLC Trials Included in the Analysis
Study Treatment
Number Analyzed
in Sex Analysis
Female Male
BR.10 Winton et al.23 Cisplatin 50 mg/m2 d1 8 q4 wk  4 cycles  vinorelbine
25 mg/m2 weekly  16a
79 152
vs
Observation
BR.14 Gridelli et al.24 Cisplatin 80 mg/m2 d1  vinorelbine 30 mg/m2 on d1 d8
q3 wk  6 cycles
35 57
or
Cisplatin 80 mg/m2 d1  gemcitabine 1200 mg/m2 d1 8
q3 wk  6 cycles
vs
Vinorelbine 25 mg/m2  gemcitabine 1000 mg/m2 d1 8 q3
wk  6 cycles
BR.18 Leighl et al.25 Carboplatin AUC 6  paclitaxel 200 mg/m2 d1 q3 wk, up to
8 cycles, plus oral BMS-275291 1200 mg daily (until
disease progression or intolerable toxicity)
206 561
vs
Carboplatin AUC 6  paclitaxel 200 mg/m2 d1 q3 wk, up to
8 cycles, plus oral placebo daily (until disease progression
or intolerable toxicity)
a 18 patients were treated with vinorelbine 30 mg/m2 before a protocol amendment.
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Assessment
The primary end points of this analysis were efficacy,
AE, dose delivery, and QoL. The primary efficacy end points
included OS, progression-free survival (PFS), or relapse-free
survival (RFS) and tumor response. Responses were mea-
sured using the World Health Organization criteria in
BR.1426 and RECIST (Response Evaluation Criteria in
Solid Tumors) in BR.18.27 PFS (BR.14 and BR.18) and
RFS (BR.10) were pooled and calculated from the date of
randomization until the date of the event. OS was calcu-
lated from the date of randomization until the date of death
or date of last follow-up.
AEs were graded and reported using NCIC CTG ex-
panded toxicity criteria (BR.10), World Health Organization
toxicity criteria (BR.14),26 and National Cancer Institute
Common Toxicity Criteria (NCI CTC) version 2 (BR.18).28
Both hematological (neutropenia, anemia, thrombocytopenia,
and febrile neutropenia) and nonhematological (emesis, mu-
cositis, fatigue, diarrhea and nonneutropenic infection) AEs
were assessed, because these had been found to differ be-
tween sexes in previous studies.9 All common and important
AEs (grade 1 and above) and severe AEs (grade 3 and 4) were
reported, regardless of their relationship to study medication.
DI was calculated by the total dose of chemotherapy
delivered divided by the total planned dose. The number of
treatment delays or dose reductions was calculated for each
patient. For patients who received more than the planned 6
cycles in BR.18, DI was calculated by dividing the total dose
given and the total dose planned by the number of weeks of
treatment. The total dose of chemotherapy administered and
the number of dose reductions were calculated using all
included patients from the start of treatment until completion
of the last cycle of chemotherapy.
QoL was assessed in all trials using the European
Organization for Research and Treatment of Cancer QoL
questionnaire QLQ-C30 and the lung cancer-specific QoL
module QLQ-LC13.29,30
Statistical Methods
To evaluate an overall patient sex effect while control-
ling for the effect of treatment received, all analyses were
performed stratified by treatment arm whenever applicable.
Mantel-Haenszel tests were used to compare the characteris-
tics of patients, response rates, AEs, and dose delivery be-
tween sexes. Stratified logistic regression was performed to
examine for potentially confounding covariates including
age, performance status, body surface area, pathologic sub-
type, and hemoglobin level at baseline. Survival curves were
estimated by the Kaplan-Meier method and compared with
the stratified log-rank test between different groups. Cox
regression models, stratified by treatment received, were used
to study the effect of patient sex while adjusting for prognos-
tic factors.
In assessing changes in QoL, the Cochran-Armitage
test was used to detect trends in QoL in each study, and the
Mantel-Haenszel test was used in the pooled database to test
the trend stratified by treatment received.31 For functional
domain scores, patients were classified as improved if there
was a score10 points higher than baseline at any time point
in the assessment period or worsened if there was a drop in
score of 10 points without the aforementioned defined
improvement, and the rest were classified as stable. For
symptom domains and single items, the classification of
responses was reversed because lower scores from baseline
indicate improvement.
RESULTS
Patients
Of 1757 patients randomized into the 3 trials, 409
Italian patients were excluded from the BR.14 study because
their data were not held by NCIC CTG. The 240 patients in
the observation arm of BR.10 were excluded. A total of 1108
patients were analyzed for survival, of whom there were 326
females (29%) and 782 males (71%). Eighteen patients (11 in
BR.10 and 7 in BR.18) were not treated and therefore
excluded from the AEs and QoL analyses (Figure 1). Base-
line patient characteristics are shown in Table 2.
Women were more likely to have adenocarcinoma
histology (70% versus 44%, p  0.0001), and using body
mass index, were more likely to be either of normal weight or
underweight than men (60% versus 49%, p  0.0001).
Conversely, women were less likely to be anemic at baseline
(29% versus 55%, p  0.0001), or to have other comorbidi-
ties such as diabetes mellitus, ischemic heart disease, hyper-
tension, or chronic obstructive pulmonary disease (32% ver-
sus 47%, p  0.0001). A history of cigarette smoking was
only recorded in the BR.10 study, where 7 women (9%) in the
chemotherapy arm were never smokers, whereas none of the
men was classified as a never smoker (p  0.0001).
Efficacy
Response rates, measured in BR.14 and BR.18, were
not significantly different between women and men (27%
versus 31%, p  0.44).
PFS was significantly longer in women in both univar-
iate (hazard ratio [HR] for disease progression 0.80, 95%
confidence interval [CI] 0.69–0.93, p  0.003) (Figure 2A)
and multivariate analysis (adjusting for age, stage at random-
ization, treatment arm, baseline hemoglobin, body surface
area, and performance status) (HR 0.83, 95% CI 0.71–0.97,
p  0.02).
In univariate analysis, women had a significantly longer
OS than men (HR 0.81, 95% CI 0.68–0.95, p 0.01) (Figure
2B), but this was not statistically significant in multivariate
analysis (HR 0.89, 95% CI 0.75–1.05, p  0.17).
In multivariate analysis (adjusting for the same factors
as for PFS), only baseline anemia was a predictor of poor OS,
where patients with  grade 1 anemia at baseline had a HR
for death of 1.60 (95% CI 1.37–1.86, p  0.0001). Baseline
anemia also predicted for shorter PFS (HR 1.34, 95% CI
1.17–1.54, p  0.0001), as did nonsquamous, nonadenocar-
cinoma histology (HR 1.34, 95% CI 1.11–1.63, p  0.003).
When assessing the effect of patient sex in the individ-
ual studies, longer PFS and OS in women was observed in all
studies. In BR.10 (n  242), women had longer RFS (not
reached versus 72 months, HR 0.69 [0.45–1.06], p  0.09)
and OS (94 versus 78 months, HR 0.65 [0.40–1.05], p 
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TABLE 2. Comparison of Baseline Patient Characteristics by Sex
Female
n  320 (29%)
Male
n  770 (71%) p
Trials and treatment groups
Trial
BR.10 (number analyzed  231) 79 (34%) 152 (66%) 0.02
BR.14 (number analyzed  92) 35 (38%) 57 (62%)
BR.18 (number analyzed  767) 206 (27%) 561 (73%)
Treatment group
BR.10 Vin Cis (n  231) 79 (34%) 152 (66%) 0.01
BR.14 Gem Cis (n  23) 10 (43%) 13 (56%)
BR.14 Gem Vin (n  46) 18 (39%) 28 (61%)
BR.14 Cis Vin (n  23) 7 (30%) 16 (70%)
BR.18 Pac Carbo placebo (n  385) 103 (27%) 282 (73%)
BR.18 Pac Carbo BMS (n  382) 103 (27%) 279 (73%)
Patient demographics
Age
65 209 (65%) 520 (67%) 0.40
65 111 (35%) 250 (32%)
Stage (at surgery in BR.10, at randomization
in BR.14 and BR.18)
I 39 (12%) 64 (8%) Not applicablea
II 40 (12%) 88 (11%)
III 40 (12%) 134 (17%)
IV 201 (63%) 484 (63%)
Body surface area (BSA)
2 305 (95%) 581 (75%) 0.0001
2 15 (5%) 189 (25%)
Body mass index (BMI) (weight
kg/height m2)
Underweight (18.5) 28 (9%) 28 (4%) 0.0001
Normal weight (18.5–24.9) 162 (51%) 344 (45%)
Overweight (25.0–29.9) 81 (25%) 275 (36%)
Obese (30.0) 47 (15%) 111 (15%)
ECOG performance status
0 118 (37%) 247 (32%) 0.52
1 175 (55%) 449 (58%)
2 or 3 27 (8%) 74 (10%)
Pathological subtype
Adenocarcinoma 223 (70%) 338 (44%) 0.0001
Squamous cell carcinoma 32 (10%) 246 (32%)
Other 65 (20%) 186 (24%)
Baseline hemoglobin
Grade 0 226 (71%) 346 (45%) 0.0001
Grade 1 or more 93 (29%) 421 (55%)
Comorbidities
Any comorbidity 103 (32%) 363 (47%) 0.0001
Diabetes mellitus 9 (3%) 64 (8%) 0.001
Ischaemic heart disease 4 (1%) 26 (3%) 0.06
Cerebrovascular disease 8 (2%) 14 (2%) 0.46
Hypertension 69 (22%) 219 (28%) 0.02
COPD 33 (10%) 156 (20%) 0.0002
a Trials were stratified by stage.
Vin, vinorelbine; Cis, cisplatin; Gem, gemcitabine; Pac, paclitaxel; Carbo, carboplatin; BMS, BMS-275291; ECOG, Eastern
Cooperative Oncology Group; COPD, chronic obstructive pulmonary disease.
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0.08) than men. In BR.14 (n  92), women had longer PFS
(5.6 versus 4.1 months, HR 0.77 [0.47–1.28], p  0.31) and
OS (11.9 versus 8.9 months, HR 0.74 [0.39–1.44], p  0.38)
than men.
In BR.18 (n 774), women had longer PFS (5.2 versus
4.8 months, HR 0.82 [0.70–0.97], p  0.02) and OS (9.5
versus 8.8 months, HR 0.84 [0.70–1.01], p 0.06) than men.
In BR.18, data were also available on postprotocol lines of
therapy. Second-line therapy was administered to 46% of
patients, and when this was included in the multivariate
analysis, female sex remained a significant predictor of
longer survival (HR 0.83 [0.69–1.00], p  0.046).
Adverse Events
There was no statistically significant difference in se-
vere (grade 3 or 4) AEs between the sexes in any of the trials
or in the pooled analysis (Table 3). Women were more likely
to report nausea or vomiting of any grade than men (78%
versus 66%, p  0.0004), but the difference was only a trend
when confined to grade 3 or 4 (10% versus 6%, p  0.077).
Women were less likely to experience anemia of any grade
(91% versus 98%, p  0.0001), but there was no significant
difference in grade 3 or 4 anemia (9% versus 10%, p 0.85).
In a stepwise logistic regression analysis, patient sex and
baseline hemoglobin correlated with the risk of anemia. The
use of erythropoietin was reported in 81 cases in the BR.18
study only (23 women [11%] and 58 men [10%], p  0.74),
but this had no effect on PFS or OS. There were no significant
differences between men and women in rates of thrombocy-
topenia, neutropenia, or febrile neutropenia. There was no
significant difference in the rates of grade 5 AEs (death) of all
causalities between women and men (1% versus 2%).
Treatment Delivery and DI
In the pooled analysis, there was no significant differ-
ence in the number of dose reductions or dose delays required
between women and men. In BR.18, women were more likely
to have carboplatin doses omitted (8% versus 3%, p 0.002)
or treatment delays because of hematological toxicity (16%
versus 10%, p  0.02). There was no difference in the DI of
cisplatin, carboplatin, vinorelbine, or paclitaxel between the
sexes.
Quality of Life
There were no major differences in compliance be-
tween women and men at baseline or at any time point in each
of the trials. In the pooled analysis, there were no significant
differences in any QoL measures between women and men.
In the global QoL score, 50% of women reported improve-
ment compared with 42% of men (p  0.11). There were no
significant differences in rates of improvement of the main
lung cancer symptoms between women and men (cough: 37%
versus 41%, p  0.97; dyspnea: 35% versus 34%, p  0.98;
pain: 59% versus 60%, p  0.83). In addition, no significant
differences between sexes were seen in cognitive, emotional,
financial, role, or social function (Table 4).
In BR.10, women reported more improvements in dys-
pnea (38% versus 26%, p  0.03), cognitive function (38%
versus 20%, p 0.02), emotional function (62% versus 36%,
p  0.004), social function (69% versus 48%, p  0.04), and
global QoL (62% versus 39%, p  0.007) than men.
DISCUSSION
In this retrospective pooled analysis of NCIC CTG
NSCLC phase III trials, we demonstrate only small efficacy
and AE differences between women and men. No significant
difference in response rate was observed between sexes, and
although a modest improvement in PFS was seen among
women, OS was not significantly different in multivariate
analysis. This is in contrast to our analysis of the influence of
sex in NCIC CTG SCLC trials where we demonstrated a clear
efficacy benefit for women,9 a finding that has been demon-
strated in other SCLC studies.32,33 Given the difference in
observations of PFS and OS, postprotocol therapy was inves-
tigated in BR.18 (the only study that collected such data).
When second-line therapy was included in the multivariate
model, female sex remained a predictor of longer OS.
Evidence that treatment with chemotherapy may be
more effective in women with NSCLC is increasing. Al-
though two previous analyses of the role of sex on outcomes
from chemotherapy showed no significant difference in re-
sponse rates,18,22 a number of studies have shown an OS
benefit to women. Two published series from the Southwest
Oncology Group reported female sex to be a positive prog-
FIGURE 2. Progression-free survival (A) and overall survival
(B) by sex in the pooled database.
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nostic factor, although in the more recent analysis, the effect
seemed to be limited to women older than 60 years.16,17
Retrospective analyses of the E1594 study of four chemo-
therapy regimens in advanced NSCLC, the European Orga-
nization for Research and Treatment of Cancer 08975 study
(cisplatin/gemcitabine, cisplatin/paclitaxel, or gemcitabine/
paclitaxel in advanced NSCLC), and a Mayo Clinic series all
reported a small median survival advantage for women over
men.21,22,34 HRs reported in these series are similar to that
found in our analysis, although the difference in our study
was not statistically significant (HR 0.89, 95% CI 0.75–1.05,
p 0.17), perhaps due to slightly smaller numbers. Although
there are three other series that do not report a statistically
significant survival advantage for women (one of which was
a pooled analysis that included the previously mentioned
E1594 study),18,20,35 it would seem that women with NSCLC
likely do experience modestly longer survival than men when
treated with chemotherapy.
In our analysis, some AE differences were observed
between sexes. Women experienced more nausea and vom-
iting of any grade, although differences in grade 3 or 4 emesis
did not reach statistical significance. Our similar analysis of
TABLE 3. Comparison of Adverse Events by Sex
Grade Adverse Event Variable Female Male p
Hematological parameters
 Grade 1 Hemoglobin 291 (91%) 753 (98%) 0.0001
Platelets 172 (54%) 412 (54%) 0.72
Neutrophils 273 (86%) 624 (81%) 0.14
 Grade 3 Hemoglobin 30 (9%) 78 (10%) 0.85
Platelets 22 (7%) 46 (6%) 0.49
Neutrophils 207 (65%) 465 (61%) 0.18
Febrile neutropenia 22 (7%) 65 (8%) 0.42
Nonhematological parameters
 Grade 1 Stomatitis 69 (22%) 139 (18%) 0.17
Nausea/vomiting 249 (78%) 506 (66%) 0.0004
Infection (nonneutropenic) 97 (30%) 217 (28%) 0.53
Fatigue 261 (82%) 615 (80%) 0.57
Renal 37 (12%) 117 (15%) 0.06
Neuropathy 180 (56%) 452 (59%) 0.98
Anorexia 151 (47%) 377 (49%) 0.78
 Grade 3 Stomatitis 4 (1%) 9 (1%) 0.84
Nausea/vomiting 31 (10%) 48 (6%) 0.08
Infection (nonneutropenic) 19 (6%) 66 (9%) 0.20
Fatigue 56 (17%) 129 (17%) 0.67
Renal 3 (1%) 16 (2%) 0.22
Neuropathy 29 (9%) 92 (12%) 0.33
Anorexia 13 (4%) 40 (5%) 0.35
Grade 5 adverse events (death) of
all causalities
2 (1%) 15 (2%) 0.18
TABLE 4. Comparison of Quality of Life by Sex
Female (%) Male (%)
pImproved Stable Worse Improved Stable Worse
Cognitive function 33 30 37 28 34 38 0.44
Emotional function 53 27 20 45 32 24 0.21
Physical function 39 22 39 32 27 42 0.38
Role function 47 20 34 35 27 38 0.11
Financial concerns 21 61 17 22 56 22 0.60
Nausea 27 39 34 22 44 34 0.54
Cough 37 39 24 41 33 26 0.97
Dyspnea 35 35 30 34 38 29 0.98
Pain 59 16 26 60 13 27 0.83
Global QoL 50 21 28 42 23 35 0.11
QoL, quality of life.
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SCLC trials from NCIC CTG reported that women experi-
enced more hematological and nonhematological toxicities
than men.9 When comparing the two analyses, the propor-
tions of women and men experiencing nausea or vomiting of
any grade are similar (NSCLC: 78% versus 66%; SCLC: 77%
versus 67%), and in both studies, the difference in grade 3
and 4 emesis outcomes just failed to reach statistical signif-
icance (NSCLC: p  0.08; SCLC: p  0.06). Higher rates of
nausea and vomiting in women were also reported in the
E1594, TAX 326, and NCCTG publications.18,20,22 It is in-
teresting to note that in phase III trials investigating the
neurokinin-1 antagonist, aprepitant, in chemotherapy-induced
nausea and vomiting, women had lower rates of emesis
control in the control arm, but with the addition of aprepitant,
the rates of chemotherapy-induced nausea and vomiting fell
in both men and women and there was no longer a significant
difference between sexes.36 We observed no difference in the
rates of stomatitis in this study, although previous studies
have reported that women may expect higher rates of stoma-
titis/mucositis.9,10
As expected, given the relatively small differences in
AEs, there were no significant differences seen in dose delays
or dose reductions between sexes. We could find no previous
reports of DI differences in NSCLC, but our SCLC analysis
demonstrated that women were more likely to have treatment
delays of more than 2 weeks (52% versus 43%, p  0.02),9
although an older analysis of 1521 patients with SCLC
reported no sex differences in DI.33
To our knowledge, this is the first analysis that has
examined QoL differences between sexes in a pooled dataset
of lung cancer trials. In the adjuvant BR.10 study, among
those patients in the chemotherapy arm, women reported
greater improvements in dyspnea, cognitive function, emo-
tional function, social function, and global QoL than men.
However, when combined with the data from the BR.14 and
BR.18, studies of chemotherapy in advanced disease, the
benefits were no longer seen. Caution is needed in this mixed
dataset, however, because QoL in the adjuvant setting may be
quite different to the palliative setting. One might expect QoL
to deteriorate in the adjuvant setting because of toxicity of
treatment, whereas in the metastatic setting this may be
offset by an improvement in cancer symptoms if the cancer
burden is reduced. It would be interesting to see if more
QoL differences would be reported in a situation where
there was a clearer difference in either efficacy or toxicity
between sexes.
Nausea as a QoL measure was not different between
genders in this analysis, although women reported more
nausea and vomiting as an AE. This discrepancy is most
likely explained by timing of the measurements. QoL mea-
sures were recorded as how the patient felt when the ques-
tionnaire was administered just before chemotherapy. AE
recording accounts for nausea occurring at any point in each
cycle, which was more likely in the first days after treatment.
It is possible that although women may report more nausea
than men, it may not particularly affect their daily QoL.
There is little comparable data on gender differences in
QoL outcomes in cancer. Female terminal care cancer pa-
tients have reported higher rates of nausea and vomiting than
men, using the QLQ-C30 questionnaire.37 In patients with
locally advanced NSCLC, assessed before treatment using
the Functional Living Index-Cancer scale, women reported
lower scores, i.e., worse QoL, than men.38 Elderly women
with cancer have reported lower QoL scores, lower sense of
coherence, and greater economic and social concerns than
elderly men with cancer.39 Women have also reported worse
global health and physical functioning after rectal cancer
surgery or coronary artery bypass surgery,40,41 and worse
health-related QoL scores in chronic obstructive pulmonary
disease patients.42 In addition, women have reported higher
fatigue scores and more depression than men in a number of
studies.43–47
Survival advantages for women are more clearly seen
in SCLC rather than NSCLC. As both types of cancer are
treated most commonly with platinum-based chemotherapy,
it would seem less likely that sex-based differences in drug
metabolism contribute a great deal, although variable drug
distribution because of body habitus differences between
sexes, and sex differences in cytochrome P450 activity have
been proposed as hypotheses.48 There is little evidence avail-
able to support clear differences in drug metabolism of
specific cancer drugs. Methods of calculating glomerular
filtration rate used in carboplatin dosing include the Cockroft-
Gault, Calvert, Chatelut, and the Jelliffe formulae. Depending
on which formula is used, the doses may vary between
sexes.49,50 A study of pharmacokinetics in 168 patients with
solid tumors, including 84 NSCLC patients, demonstrated
that sex significantly and independently affected paclitaxel
distribution and elimination, where males had a 20% higher
maximal elimination capacity.51 We could find no reports of
sex differences in drug metabolism of cisplatin, vinorelbine,
or gemcitabine. Therefore, the hypothesis that women have
higher DI, perhaps due to pharmacokinetic or pharmacody-
namic differences, leading to greater toxicity and improved
survival remains plausible, although this analysis cannot
strongly support it.
The trials we reviewed in this retrospective analysis
were heterogeneous, containing patients treated in both the
adjuvant and metastatic setting. However, it would seem
unlikely that tumor biology differences in early stage and late
stage disease would vary by patient sex; indeed numerically
longer PFS/RFS and OS for women were seen in each of our
trials analyzed, even if this only reached statistical signifi-
cance in BR.18, the study that contributed the largest number
of patients. Furthermore, cigarette smoking history was not
widely available, particularly in the metastatic trials. Women
with lung cancer are more likely to be never smokers, and a
history of never smoking is a positive prognostic factor.52 We
were unable to control for this in our analysis, and the
interplay among patient sex, smoking history, histology, and
outcomes is clearly an area for future research. Concomitant
medications may differ between sexes, particularly as we
demonstrated a higher level of comorbidities in men. The
potential influence of these drugs on chemotherapy and the
measured outcomes is unknown. The role of activating EGFR
mutations is also of interest following observations that
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responses to the EGFR tyrosine kinase inhibitors are more
common in women and never smokers. In an exploratory
analysis from the BR.10 study, activating EGFR mutations
were not found to be prognostic for OS or predictive of a
benefit from adjuvant chemotherapy.53
In conclusion, this analysis demonstrates modest dif-
ferences in efficacy and toxicity outcomes between women
and men receiving chemotherapy for NSCLC. Decisions
regarding the choice of chemotherapy should not be influ-
enced by patient sex.
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